Galapagos’s experimental bowel disease treatment, named GLPG1205, has failed to meet the end point of its clinical trial.
The Belgium-based biotechnology company will discontinue clinical development of the drug.
Galapagos carried out an ORIGIN study that showed GLPG1205 did not differentiate from the placebo on (partial) Mayo scores.
The company added that GLPG1205 was shown to be overall safe and well-tolerated by patients in the ORIGIN study.
It claimed that the exposure data was in line with healthy volunteer data from the previous Phase 1 clinical study.
Galapagos will publish further details of the ORIGIN study later this year.
A first-in-class molecule, GLPG1205 targets and inhibits GPR84, a free fatty acid receptor which triggers the onset and aggravation of UC.
It is also effective in combating inflammatory bowel diseases (IBD).
GLPG1205 was administered on patients during Origin Proof-of-Concept Phase 1 and 2 trials.
The Phase 1 study involved oral administration of single and multiple ascending doses of GLPG1205, which has exhibited a complete inhibition of GPR84 and favourable properties.
Galapagos chief scientific officer Dr Piet Wigerinck previously said: "We are pleased that recruitment for the ORIGIN study has gone so well, which means we can report topline results one quarter earlier than planned."
The successful first test prompted Galapagos to conduct the Phase 2A study measuring the efficacy of GLPG1205 in treating inflammatory bowel disease (IBD).
Started in January 2015, The Phase 2 test subjected patients from six countries to oral doses of GLPG1205.
Aside from exhibiting tolerance, patients treated with significant impact of GLPG1205 in treating UC apart from being exhibiting tolerance with the patients.
Galapagos is exploring options to develop GLPG1205 in alternative indications.